NVRO Stock Overview
A medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nevro Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.79 |
| 52 Week High | US$22.53 |
| 52 Week Low | US$3.52 |
| Beta | 0.83 |
| 1 Month Change | -16.15% |
| 3 Month Change | -33.74% |
| 1 Year Change | -82.37% |
| 3 Year Change | -95.60% |
| 5 Year Change | -96.74% |
| Change since IPO | -84.95% |
Recent News & Updates
Recent updates
Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding
Aug 11
Nevro: Not Having My Back
Aug 09Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Jul 16Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
May 01Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Feb 25There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding
Jan 08Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Nov 16Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold
Sep 01Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?
Jul 10Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings
Feb 28Nevro falls to 52-week low; down ~49% over last year
Feb 22Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains
Feb 14Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Jan 13Nevro: Opportunity Overshadowed By Weaknesses
Dec 07Boston Scientific drives rival Nevro lower after remarks on neuromodulation
Oct 26Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval
Oct 13Nevro gets FDA approval for Costa Rica manufacturing operations
Oct 04Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Oct 02Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation
Sep 07Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Jun 17Shareholder Returns
| NVRO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.9% | -1.5% | -2.4% |
| 1Y | -82.4% | 10.0% | 23.4% |
Return vs Industry: NVRO underperformed the US Medical Equipment industry which returned 10% over the past year.
Return vs Market: NVRO underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| NVRO volatility | |
|---|---|
| NVRO Average Weekly Movement | 10.1% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NVRO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NVRO's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1,215 | Kevin Thornal | nevro.com |
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands.
Nevro Corp. Fundamentals Summary
| NVRO fundamental statistics | |
|---|---|
| Market cap | US$142.02m |
| Earnings (TTM) | -US$69.31m |
| Revenue (TTM) | US$419.15m |
0.3x
P/S Ratio-2.0x
P/E RatioIs NVRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVRO income statement (TTM) | |
|---|---|
| Revenue | US$419.15m |
| Cost of Revenue | US$134.06m |
| Gross Profit | US$285.09m |
| Other Expenses | US$354.40m |
| Earnings | -US$69.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 68.02% |
| Net Profit Margin | -16.54% |
| Debt/Equity Ratio | 81.2% |
How did NVRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:14 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nevro Corp. is covered by 26 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| null null | Baird |
| Michael Polark | Baird |